Brought to you by 
Merck to co-promote Daxas with Nycomed in Europe and Canada; deals ends
18 Jan 2012
Executive Summary
Nycomed International Management GMBH has granted Merck & Co. Inc. rights to market Daxas (roflumilast) for chronic obstructive pulmonary disease (COPD) in certain European countries and Canada.
Deal Industry
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck to co-promote Daxas with Nycomed in Europe and Canada; deals ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice